



RECEIVED  
SEP 06 2001

TECH CENTER 1600/2900

48. ~~A48.~~ <sup>34</sup>Amended. An immunotherapy method of treating a human ~~in clinical need thereof~~ suffering from a disease or disorder, which method comprises the steps of:

(i) constructing a first recombinant expression vector encoding a light chain of a therapeutically effective antibody and constructing a second expression vector encoding a heavy chain of said therapeutically effective antibody;

(ii) introducing said vectors of step (i) into a Chinese hamster ovary (CHO) cell;

(iii) culturing said CHO cell in a culture medium so that said light and heavy chains are produced and a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;

(iv) recovering said therapeutically effective recombinant antibody of step (iii);

(v) administering the recombinant antibody of step (iv) in a therapeutically effective amount to said human.

49. (Amended) The method of claim 48 wherein the recombinant antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

58. A (Amended) An immunotherapy method of treating a human ~~in clinical need thereof~~ suffering from a disease or disorder, which method comprises the steps of:

(i) transforming a Chinese hamster ovary (CHO) cell with a recombinant expression vector such that said cell can express ana recombinant antibody;

(ii) culturing said CHO cell in serum-free medium so that a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;

(iii) recovering said therapeutically effective recombinant antibody of step (ii);

(iv) administering the recombinant antibody of step (iii) in a therapeutically effective amount to said human.

59. (Amended) The method of claim 58 wherein the recombinant antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

61. (Amended) The method of claim 60, wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.

48.—A48. (Amended) An immunotherapy method of treating a human ~~in clinical need thereof~~suffering from a disease or disorder, which method comprises the steps of:

(i) constructing a first recombinant expression vector encoding a light chain of a therapeutically effective antibody and constructing a second expression vector encoding a heavy chain of said therapeutically effective antibody;

(ii) introducing said vectors of step (i) into a Chinese hamster ovary (CHO) cell;

(iii) culturing said CHO cell in a culture medium so that said light and heavy chains are produced and a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;

(iv) recovering said therapeutically effective recombinant antibody of step (iii);

(v) administering the recombinant antibody of step (iv) in a therapeutically effective amount to said human.

49. (Amended) The method of claim 48 wherein the recombinant antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

58. A(Amended) An immunotherapy method of treating a human ~~in clinical need thereof~~suffering from a disease or disorder, which method comprises the steps of:

(i) transforming a Chinese hamster ovary (CHO) cell with a recombinant expression vector such that said cell can express ana recombinant antibody;

(ii) culturing said CHO cell in serum-free medium so that a CHO glycosylated therapeutically effective recombinant antibody is thereby produced;

(iii) recovering said therapeutically effective recombinant antibody of step (ii);

(iv) administering the recombinant antibody of step (iii) in a therapeutically effective amount to said human.

59. (Amended) The method of claim 58 wherein the recombinant antibody is a human, chimaeric, CDR-grafted or bi-specific antibody.

61. (Amended) The method of claim 60, wherein the T-cell disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.